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Abstract 
 
The use of 5-fluorouracil (5-FU) in colon cancer as the primary chemotherapy has not been 
meet satisfactory effectiveness. Therefore, the development of new chemicals as a chemopreventive 
agent and a combination agent (co-chemotherapeutic agent) for colon cancer is important.  
Pentagamavunone-0 (2,5-bis-(4'-hydroxy-3'-methoxybenzylidine) cyclopentanone) (PGV-0), one of 
curcumin analogs, exhibits cytotoxic effect and apoptosis induction in various cancer cell lines, 
including colon cancer cell, better than curcumin. This study aimed to investigate the cytotoxic 
potency of PGV-0 in combination with 5-FU and their effects, in single or in combination, on cell 
cycle toward WiDr colon cancer cell line. The cells were treated with combination concentrations 
of PGV-0 and 5-FU, and examined by MTT cell viability assay. The value of combination index (CI) as 
a parameter of cytotoxic combination assay was measured by a combination index method. Cells 
were stained with propidium iodide and the cell cycle distribution was determined by flowcytometry. 
CI calculation showed additive effects between PGV-0 and 5-FU. Combination of PGV-0 and 5-FU 
gave synergism on cell cycle. Single treatment of PGV-0 increased apoptosis, illustrated as subG1-
phase accumulation, stronger than single treatment of 5-FU. Meanwhile, combination of PGV-0 and 
5-FU demonstrated S-phase arrest. Based on these results, it can be concluded that PGV-0 has the 
potential to be developed as a co-chemotherapeutic agent for colon cancer but still requires further 
tracking of its molecular mechanisms. 
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INTRODUCTION 
 
 Colon cancer, one of the leading causes of 
cancer death (Jemal, et al., 2006) is one of the 
diseases suffered by many modern humans because 
of the shift in dietary that tends to be less fiber and 
high fat. Colon cancer chemotherapy uses 5-
fluorouracil (5-FU), a cytotoxic agent, as the main 
choice of conventional agents (Arkenau, et al., 
2005). Nevertheless, the effectiveness of therapy 
with 5-FU only reached 20%. In fact, some types of 
cancer cells show resistance to 5-FU (De Angelis, et 
al., 2006). Development of colon cancer therapy 
should be directed to find a potential chemo-
preventive agent as well as a combination agent (co-
chemotherapy) that can increase the effectiveness 
and decrease the side effects of 5-FU.Curcumin is a 
natural compound isolated from the rhizome of 
turmeric (Curcuma longa). Curcumin is known to 
have anti-inflammatory activity and is able to inhibit 
the growth of several types of cancer cells (reviewed 
by Aggarwal, et al., 2005). However, curcumin has 
low bioavailability so it does not show a significant 
effect in vivo. In spite of its bioavailability issue, 
curcumin still provides hope for colon cancer 
treatment because curcumin may last longer in the 
gastric and interact with intestinal tissue (Sharma, et 
al., 2004). Therefore, development of curcumin 
analogs to find more potent compounds, especially 
to overcome colon cancer, needs to be executed. 
 For the above purposes, National Molecule 
Team from Faculty of Pharmacy Universitas Gadjah 
Mada (UGM) has synthesized curcumin analogs 
namely Pentagamavunone-0 (PGV-0) (2,5-bis- (4'- 
hydroxy- 3' -methoxybenzylidine) - cyclopentanone) 
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 (Reksohadiprodjo, et al., 2004). PGV-0 possesses 
potent cytotoxicity against several types of cancer 
cell lines, i.e., HeLa cervical cancer cells (Meiyanto, 
et al., 2003), Raji lymphoma cells, myeloma cells 
(Da’i, 2003), T47D breast cancer cells (Da’I, et al., 
2007), WiDr colon cancer cell (Septisetyani, et al., 
2008), and MCF-7 breast cancer cells (Hermawan, et 
al., 2011). Moreover, PGV-0 shows stronger 
cytotoxicity than curcumin in breast cancer cell lines 
(Meiyanto, et al., 2006; Nurulita and Meiyanto, 
2006; Meiyanto, et al., 2014) and colon cancer cell 
line (Septisetyani, et al., 2008). PGV-0 also has low 
bioavailability (Suwaldi and Oetari, 2004), so it is 
appropriate for colon cancer treatment. Compared to 
curcumin, PGV-0 has greater potency because it 
performs better pharmacological effects, more 
stable, and does not show toxic effect based on acute 
and subchronic toxicity test in rats (National 
Molecule Team, 2001
a
; National Molecule Team, 
2001
b
). 
 Previously, it has been reported that PGV-0 
exhibits stronger cytotoxic effect and apoptotic 
induction in WiDr colon cancer cells compared to 
curcumin (Septisetyani, et al., 2008). This present 
study aimed to further investigate the potency of 
PGV-0 as co-chemotherapy agent by cytotoxicity 
assay of PGV-0 in combination with 5-FU. This 
work also investigated the effects of PGV-0, in 
single or in combination, on cell cycle toward WiDr 
cells, as a model of colon cancer cell that resistant to 
chemotherapy agents. Combination cytotoxicity 
assay and cell cycle analysis were performed as a 
preliminary step for PGV-0 development as a 
chemopreventive agent and a co-chemotherapy agent 
for colon cancer. The results of this study are 
expected to be a strong foundation for the 
development of PGV-0 for colon cancer therapy. 
 
MATERIALS AND METHODS 
 
Materials 
 PGV-0 (HPLC purity grade) was obtained 
from Curcumin Research Center (CRC) Faculty of 
Pharmacy UGM. The stock solution of PGV-0 was 
made by dissolving it in DMSO (DMSO 99.5% pro 
GC, Sigma Aldrich, Germany). 5-Fluorouracil 
(250mg/ml) preparation was from Ferron Par 
Pharmaceutical (Cikarang, Indonesia).  
 
 
Cell culture 
 WiDr colon cancer cells were a collection of 
Cancer Chemoprevention Research Center (CCRC) 
Faculty of Pharmacy UGM. Cells were grown in 
RPMI 1640 medium (Gibco, USA) supplemented by 
10% foetal bovine serum (FBS) (Gibco, USA) and 
1% (v/v) penicillin-streptomycin (Gibco, USA) and 
cultured in the CO2 incubator at 37°C. Cells were 
harvested from culture dish or flask with trypsin-
EDTA 0.025% (Gibco, Canada) at 80% confluence.   
 
Cytotoxic combination assay 
Cytotoxic combination assay was performed 
as previously described (Hermawan, et al., 2011) by 
MTT cell viability assay (Mossman, 1983). Briefly, 
the cells were plated in 96-well microplate at a 
density of 5x10
3
cells/well. Forty eight hours after 
plating, the medium was replaced with a medium 
containing single or combination of PGV-0 and 5-
FU. The following concentrations based on 
inhibitory concentration of 50% (IC50) were 
introduced : 1/8, 1/4, 3/8, 1/2 of IC50 for PGV-0 or 
1/6, 1/3, 1/2, 7/10 of IC50 for 5-FU, respectively. 
After 24 hour (h) incubation with respective 
concentration of chemicals the solution was replaced 
by 50 µg of MTT (3- (4,5-dimethyltiazole-2-yl) salt-
2,5-diphenyltetrazolium bromide) (Sigma Aldrich, 
USA) diluted in 100 µ/mL phosphate buffer saline 
(PBS) and were incubated for 3 h. One hundred 
microliter of stopper reagent  (10% SDS (Merck, 
Germay) in 0.1 N HCl (Merck, Darmstadt, 
Germany) was added and the microplate was 
incubated overnight at room temperature and 
protected from light. The absorbance at 595 nm was 
measured by a microplate reader (Biorad, Japan).  
The assay was conducted in triplicate for each 
concentration. The IC50 of PGV-0 was obtained from 
previous report (Septisetyani, et al., 2008), while the 
IC50 of 5-FU was also determined by MTT assay 
with a serial concentration of 100, 200, 300, 500, 
dan 1000 M. 
Percentage of cell viability was calculated to 
determine IC50 by a linear regression analysis (Doyle 
and Griffiths, 2000). For cytotoxic combination 
assay, combination index (CI) was calculated based 
on the combination index method (Reynolds and 
Maurer, 2005) as follow: CI = (DPGV-0/DxPGV-0) + 
(D5-FU/Dx5-FU), whereas D is the concentration of 
respective tested chemicals in combination assay and 
Ikawati, et al., 2018 
Indones. J. Cancer Chemoprevent., 9(1), 23-31  
 
25 
 
Dx is the calculated concentration of single test 
chemicals (obtained from the percent extrapolation 
of linear regression equation used to determine IC50) 
which caused the equal cell viability to the 
combination treatment (x). The value of CI is used to 
determine the potential effect given by the chemical 
combinations, whether synergistic (CI <0.1 very 
strong; 0.1-0.3 strong; 0.3-0.7 synergistic; 0.7-0.9 
weak), additive (CI 0.9-1.1), or antagonistic (CI 1.1-
1.45 weak; 1.45-3.3 antagonistic; >3.3 strong). 
 
Cell cycle modulation 
A total of 1x10
6
 cells/wells were distributed 
into a 6-well plate. After 48 h adaptation, the cells 
were treated with various concentrations of PGV-0, 
5-FU, or combination of them and then were 
incubated for 12 or 24 h. At the end of the 
incubation, floated and attached cells were collected, 
transferred into a microtube, and then centrifuged 
(2000 rpm, 3 minutes).After discarding the 
supernatant and washing in PBS, cell precipitates 
were washed with cold PBS and propidium iodide 
(PI) reagent (5% PI (Sigma Aldrich, USA)/7% triton 
X-100 (Merck, Germany)/PBS) was added. The 
microtube was incubated in a 37ºC water bath for 10 
mniutes and protected from light. The cell 
suspension was homogenized again, transferred into 
flowcyto-tube, and directly analyzed by a 
flowcytometer (FASC Calibur, Beckton Dickinson). 
Quantification of the cells in different phases of cell 
cycle was analyzed by Cell Quest software. 
 
RESULTS  
 
Cytotoxicity of 5-FU in WiDr cells 
 5-FU showed cytotoxic effects on a dose-
dependent manner in WiDr cells (Fig. 1). The IC50 
value of 5-FU was 496 μM. Therefore, the cells 
showed lower sensitivity under 5-FU treatment 
compared to PGV-0 treatment with an IC50 of 45 μM 
(Septisetyani, et al., 2008). These IC50 values were 
used to determine the concentration for cytotoxic 
combinaton assay as described in the Materials and 
Methods. 
 
 
Figure 1.  Cytotoxicity of 5-fluorouracil in WiDr cells.  Cells were treated with a serial concentration of 5-floroutacil (5-
FU) and incubated for 24 h, and then were assayed by MTT assay.  The histogram of 5-FU treatment demonstrated 
the phenomenon of dose-dependent cytotoxicity (A). Cell morphology underwent significant changes under 5-FU 
treatments compared to control (B).  Black arrow indicated a live cell; white arrow indicated a cell undergoing a 
morphological change.  The cell morphology was observed by an inverted microscope.  Scale bars = 50 µm. 
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PGV-0 synergistically increased cytotoxic 
potency of 5-FU in WiDr cells 
 Looking at the high cytotoxic potency of 
PGV-0, it is necessary to observe its potential as a 
combination agent for 5-FU in colon cancer.  The 
result of cytotoxic combination assay of PGV-0 and 
5-FU showed a strong additive effect at low 
concentration of PGV-0 (6.25 μM) with CI value of 
0.98 and 1.09 (Table 1). This value indicates that the 
combined cytotoxic effect is equal to the sum of 
each effect on a single treatment, whereas synergism 
shows that the combined cytotoxic effect is greater 
when compared to the sum of each effect on a single 
treatment. At higher concentrations there was no 
additive nor synergism effect because each 
compound has already exhibited strong cytotoxic 
effects. Histograms illustrated the cytotoxic 
combination assay of PGV-0 and 5-FU can be seen 
in Fig. 2A. 
 
Table 1.  Combination index (CI) values of cytotoxic combination assay of Pentagamavunone-0 (PGV-0) and 5-
fluorouracil (5-FU) in WiDr cells 
 
(µM) 
PGV-0 
6.25 12.5 18.75 25 
5
-F
U
 
87.5 1.13 1.61 1.72 1.02 
175 0.98* 1.58 1.54 1.14 
262.5 1.09* 1.60 1.61 1.08 
350 1.16 1.58 1.73 1.16 
*additive effect.  CI values were calculated by the combination index method (Reynolds and Maurer, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Pentagamavunone-0 at a low concentration reinforces cytotoxicity of 5-fluorouracil in WiDr cells.Cell 
viability under treatment of Pentagamavunone-0 (PGV-0) and 5-fluorouracil (5-FU) combination as described in the 
Materials and Methods was illustrated (A).  Interpretation of additive effects were illustrated based on combination 
index (CI) values calculated in Table 1 (B).  Strong additive effects were osberved at a low concentration of PGV-0.  
PGV-0 treatment at 6.25 μM induces cell morphological changes (indicated by arrows), while 175 μM of 5-FU 
treatment caused changes in cell size. The combination treatment of PGV-0 and 5-FU at their respective 
concentartion showed morphological changes as well as cell size changes.  The cell morphology was observed by an 
inverted microscope.  Scale bars = 50 µm. 
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 Cell morphological observations showed that 
the 5-FU effect was equivalent to the effect of PGV-
0. Treatment of low concentration of PGV-0 (6.25 
µM, 1/8 IC50) showed membrane permeability 
changes so the boundaries between cells became 
unclear, while the 5-FU treatment at 1/3 of IC50 (175 
µM) led to the sell size enlargement (Fig. 2B). 
Interestingly, under the combination treatment,  
boundaries between cells became unclear, cell size 
enlargements, and rounded cells were observed, 
indicating the ability of PGV-0 to increase 5-FU 
effectiveness in WiDr cells.   
 Cytotoxic effects can be caused by cell cycle 
arrest or induction of apoptosis. Mathematical 
calculations such as those done in the CI value 
calculation was used as a preliminary overview and 
as a base concentration to be used for further 
experiments. Hence, it is necessary to observe cell 
cycle modulation as a manifestation of physiological 
or morphological changes. 
 
PGV-0 single and in combination with 5-FU 
modulate WiDr cell cyle 
 Cell cycle arrest is one of the main targets of 
cytotoxic agents. The analysis of cell cycle with 
flowcytometry showed slight inhibition in the G2/M-
phase by 12 h incubation of PGV-0 at around IC50 
(50 μM) but did not induce apoptosis (Fig. 3 most 
upper panel). Nevertheless, after 24 h incubation cell 
numbers in the G2/M-phase decreased and 37.49% 
cell accumulation occured in the subG1-phase, 
indicating an increase in apoptosis (Fig. 3 lower 
panel, Table 2). Inhibition of G2/M-phase resulted in 
the cell failure to undergo mitosis. Along with the 
time, the cell that failed to divide became a polyploid 
cell and eventually undergo apoptosis (Table 2). 
 
 
 
Table 2.  WiDr cell distribution of each phase of cell cycle after Pentagamavunone-0 (PGV-0), 5-fluorouracil (5-
FU), or their combination at various concentrations 
Treatment Incubation 
(h) 
Concentration 
(µM) 
% 
SubG1 G1 S G2/M Polyploid 
Kontrol 24 - 4.71 54.05 24.81 13,55 3.37 
PGV-0  12 50 3.78 28.19 26.49 36.67a 6.03 
 24 5 10.12 48.02 19.20 12.79 10.19 
  25 8.46 33.46 24.18 13.66 20.76 
  50 37.49b  18.42 20.92 17.45 6.07 
5-FU 24 70 7.09 69.31 18.17 4.67 1.12 
  175 3.02 65.01 11.12 7.27 13.89 
  700 7.99 59.89 15.87 8.07 8.49 
PGV-0 + 5-FU 24 5 - 700 8.86 57.90 16.65 8.05 8.88 
 25 - 700 9.78 39.76 34.20c 8.51 8.43 
 6.25 - 175 2.23 74.52 12.89 6.60 4.03 
 
aG2/M-phase accumulation after 12 h treatment of PGV-0 
bSubG1-phaseaccumation, indicating apoptosis induction after 24 h treatment of PGV-0 
cCombination of PGV-0 and 5-FU resulted in S-phase arrest 
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Figure 3. Analysis of WiDr cell cycle with flowcytometry after single treatment of Pentagamavunone-0 or in 
combination with 5-fluorouracil.Cells were treated with Pentagamavunone-0 (PGV-0), 5-fluorouracil (5-FU), or 
the combination of them at various concentrations.  Cells were washed with cold PBS, centrifuged, PI reagents were 
added, and then read by FACS Caliburflowcytometry. The analysis was conducted with Cell Quest program.  
Treatment of PGV-0 for 12 h showed a slight inhibition in the G2/M-phase, whereas after 24 h incubation apoptosis 
increased. 5-FU indicates inhibition in the G1-phase. The combination of PGV-0 (25 μM) and 5-FU (700 μM) 
showed synergism in the S-phase inhibition. 
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 The inhibitory target of PGV-0 and 5-FU 
occured at different cell cycle phases as shown in 
Fig. 3. The G2/M-phase inhibition occured after 
PGV-0 treatment, whereas 5-FU, corresponding to 
its inhibition target on the activity of thymidilate 
synthase (TS) (Giovannetti, et al., 2007), inhibited 
the cell to enter the S-phase and increased cell 
accumulations in the G1-phase. The combination of 
PGV-0 and 5-FU at low concentrations producing a 
strong additive effect (CI 0.98) (Table 1) still 
showed the dominance of the 5-FU effect, which is 
the G1-phase inhibition (Fig. 3, Table 2), possibly 
because the PGV-0 effect on the cell cycle inhibition 
has not been occurred yet. Interestingly, increasing 
PGV-0 concentration (around a half of IC50) in 
combination with 5-FU shifted the cell cycle into the 
S-phase inhibition. It is possible if the incubation is 
continued (i.e., for 48 h) the triggering of apoptosis 
will be greater. 
 Overall, the observed effect of the cell cycle 
analysis was consistent with the results of the 
cytotoxic combination assay: the combination of 
PGV-0 and 5-FU for 24 h incubation did not show a 
synergistic in apoptosis induction. Synergism was 
demonstrated by the combination of PGV-0 and 5-
FU in the S-phase arrest. The combination of PGV-0 
and 5-FU in various concentrations with longer 
incubation periods needs to be observed further to 
obtain optimal cell cycle inhibition resulting in 
increased effectiveness of 5 -FU in inducing cell 
apoptosis. 
 
DISCUSSION 
 
 The main chemotherapeutic agent in colon 
cancer, 5-FU, showed a lower cytotoxic effect when 
compared to PGV-0.  5-FU, a pyrimidine analog, 
works selectively by inhibiting TS activity as the 
main mechanism of its cytotoxic effects (Shah and 
Schwartz, 2001). Although 5-FU may induce cell-
cycle inhibition and apoptosis via pathways 
dependent or independent of p53 activity, 5-FU 
shows a low cytotoxicity in colon cancer cells WiDr. 
The 5-FU chemoresistency in WiDr cells is probably 
due to mutations in the p53 tumor suppressor gene 
(Backus, et al., 2001) and the overexpression of TS 
(Sigmond, et al., 2003) and cyclooxygenase-2 
(COX-2) (Palozza, et al., 2005). 5-FU cytotoxic 
activity was not much different when WiDr was 
transfected with a vector encoding normal p53 
(Backus, et al., 2001). Therefore, increased 
sensitivity of WiDr cells, representing 5-FU-
resistant-colon cancer cells, is necessary to improve 
the effectiveness of 5-FU treatment.  
 PGV-0 is one of the potential curcumin 
analogs to be developed as a chemopreventive or co-
chemotherapy agent.  PGV-0 and Pentagamavunone-
1 (PGV)1, another curcumin analogs, have higher 
cytotoxicity and induce apoptosis strongly than 
curcumin in WiDr cells (Septisetyani, et al., 2008). 
Both of curcumin analogs also induce a proapoptotic 
protein, Bax, and COX-2 in WiDr cells 
(Septisetyani, et al., 2008). Thus, further 
investigation on the potency of PGV-0 and other 
curcumin analogs as co-chemotherapy agent for 
colon cancer is important. 
 Hermawan, et al. (2011) reported that PGV-0 
and PGV-1 are a potent co-chemotherapy agents for 
breast cancer cells by increasing apoptotic induction 
of doxorubicin and modulating cell cycle in MCF-7 
breast cancer cell line. More importantly, PGV-0 and 
PGV-1 synergisitically enhance sensitivity of MCF-
7-doxorubicin-resistant cells thorugh inhibition of 
HER2 and activation of NF-κB (Meiyanto, et al., 
2014). Accordingly, curcumin analogs, including 
PGV-0, have a prospect to be developed as co-
chemotherapy agent for another type on cancer, 
including colon cancer.  
 In this present study, PGV-0 showed the 
additive potency as a combination agent for 5-FU in 
5-FU-resistant-colon cancer cells by modulating cell 
cycle and therefore shifting the cell accumulation 
into the S-phase after 24 h treatment. It is possible if 
the incubation time is prolonged, the cells will die. 
Considering that low concentration of PGV-0 in 
WiDR was able to induce apoptosis strongly than 5-
FU, it is likely that the dying cells are also go 
thorugh apoptosis.  However, further investigated is 
needed to prove this hypothesis and also to reveal 
the molecular mechanisms behid those above 
findings. 
 Recent report by Meiyanto, et al. (2018) 
revealed that PGV-1 synergitically sensitizes WiDr 
cell to 5-FU by inhibiting NF-kB activation. Similar 
to PGV-0, PGV-1 also enhances S-phase arrest by 5-
FU. Interestingly, after 48 h incubation, the 
combination treatment of PGV-1 and 5-FU 
significantly increases the cell accumulation is the S-
phase and subG1-phase. In fact, PGV-1 and 5-FU 
Ikawati, et al., 2018 
Indones. J. Cancer Chemoprevent., 9(1), 23-31  
 
30 
 
combination suppresses level of cyclin D1, a cell 
cycle regulator. Furthermore, PGV-1 inhibits NF-kB 
activation in a luciferase reporter assay and 
decreases COX-2 expression, both at mRNA and 
protein level. Taken together those findings of PGV-
1 in WiDr cells, with further examinations it is 
possible that PGV-0 also will perform similar 
mechanisms.   
 
CONCLUSION 
 
 Analog curcumin PGV-0 has the potential to 
be developed as a chemopreventive agent or co-
chemotherapy in colon cancer therapy.  
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